The Anlon Healthcare IPO is an upcoming mainboard public offering of a pharmaceutical company based in Rajkot, Gujarat, specializing in the manufacture of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Founded in 2013, Anlon Healthcare serves domestic and select international markets, focusing on raw materials used in medicines and nutraceuticals. The Anlon Healthcare IPO is scheduled from August 26 to August 29, 2025, with a price band of ₹86 to ₹91 per share and a face value of ₹10 each.
₹5
₹91
₹92.00
Expert Opinions
The Anlon Healthcare IPO has witnessed positive market sentiment driven by its focus on manufacturing high-purity pharmaceutical intermediates and APIs. Company strengths include a strategically located manufacturing facility, adherence to global quality standards, and a robust pipeline with expanding production capacity. For the financial year 2025, key valuation metrics include a Return on Capital Employed (ROCE) of 21.93%, a Return on Net Worth (RoNW) of 25.21%, and an EBITDA margin of 26.88%, reflecting strong operational efficiency and profitability.
Risks consist of regulatory challenges, competition in a fragmented pharmaceutical sector, and dependence on limited product lines. From a long-term investment perspective, the Anlon Healthcare IPO offers potential growth aligned with increasing global demand for pharmaceutical raw materials and strengthened market positioning.
Investor Considerations
The Anlon Healthcare IPO offers investors an opportunity to participate in a pharmaceutical API and intermediates manufacturer with improving financials and growth prospects. The company reported a Price to Book Value of 4.51, PAT margin of 17.06%, and a Debt-to-Equity ratio of 0.73 for FY 2025, reflecting healthy profitability and moderate leverage. The pharmaceutical sector is growing steadily, driven by rising demand for quality APIs globally. Anlon Healthcare’s focus on capacity expansion and innovation positions it well for the future.
Risks include regulatory changes, intense competition, and dependency on limited product lines. The Anlon Healthcare IPO is suited for long-term investors looking for exposure to pharmaceutical manufacturing growth, while short-term investors should be mindful of market fluctuations and execution risks.
| Date | GMP | Trend |
|---|---|---|
| 26 Aug 2025 12.01 | ₹5 | --- |
| 25 Aug 2025 15.45 | ₹5 | Up |
| 24 Aug 2025 11.55 | ₹00 | --- |
| 23 Aug 2025 18.26 | ₹00 | --- |
| 22 Aug 2025 10.54 | ₹00 | --- |
| 21 Aug 2025 11.24 | ₹00 | --- |
| 20 Aug 2025 17.31 | ₹00 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Anlon Healthcare IPO’s listing performance. With a final GMP of ₹5, it projected a premium of 5.49% over the issue price of ₹91. The stock listed at ₹92, delivering a gain of 1.10%. This resulted in a moderate prediction error of 4.39%, where the GMP correctly signaled a positive listing but slightly overestimated the actual gain, reflecting fair reliability in this case.
Anlon Healthcare IPO Current GMP is ₹5.
Anlon Healthcare IPO Expected Returns is 5.49%.
Anlon Healthcare IPO estimated listing price is ₹96.